Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Sold by Logos Global Management LP

Logos Global Management LP trimmed its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 77.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 500,000 shares of the biotechnology company’s stock after selling 1,744,960 shares during the period. Logos Global Management LP owned 0.91% of Astria Therapeutics worth $4,550,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. RA Capital Management L.P. bought a new position in shares of Astria Therapeutics during the first quarter worth about $62,115,000. Perceptive Advisors LLC grew its position in shares of Astria Therapeutics by 82.9% during the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after acquiring an additional 1,814,608 shares during the last quarter. Armistice Capital LLC bought a new position in shares of Astria Therapeutics during the fourth quarter worth about $12,119,000. Artal Group S.A. bought a new position in shares of Astria Therapeutics during the first quarter worth about $12,445,000. Finally, Vanguard Group Inc. grew its position in shares of Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after acquiring an additional 480,184 shares during the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Trading Down 3.3 %

NASDAQ:ATXS opened at $12.23 on Tuesday. Astria Therapeutics, Inc. has a twelve month low of $4.26 and a twelve month high of $16.90. The firm has a market cap of $671.59 million, a price-to-earnings ratio of -5.27 and a beta of 0.71. The company has a 50-day moving average of $11.33 and a 200-day moving average of $10.89.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). On average, research analysts forecast that Astria Therapeutics, Inc. will post -1.66 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Oppenheimer upped their price target on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Finally, TD Cowen started coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Astria Therapeutics currently has an average rating of “Buy” and an average price target of $25.20.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.